Absorbable Tissue Spacer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

Absorbable Tissue Spacer Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The absorbable tissue spacer market studied is anticipated to grow with a CAGR of 4.9%, during the forecast period.

The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. Due to the fragility and immunosuppression, oncologic patients were reported to be at higher risk of COVID-19 complications and deaths. Hence, government initiatives were taken to overcome the complications. For instance, according to an article published by SAGE Publications, in December 2021, during the COVID-19 pandemic, the Regional Health Council converted selected hospitals for cancer care in oncologic hubs to create COVID-19-free zones and guarantee the continuation of cancer treatments safely. The European Institute of Oncology (IEO) IRCSS (Milan, Italy) was one of those. Therefore, even though the COVID-19 pandemic significantly impacted market growth in the initial phases, cancer treatments resumed following government initiatives, which significantly impacted the absorbable tissue spacer market. Additionally, as the COVID-19 cases started to decline, the market has returned to the normal levels of demand for radiotherapy and is anticipated to show significant growth over the forecast period.

Certain factors that are driving the market growth include the increasing prevalence of cancer and the advantages associated with tissue spacers. The growing number of people suffering from various cancers is the key driving factor for the growth of the market. For instance, as per the data published by the American Cancer Society in January 2023, around 1,958,310 people are expected to be diagnosed with new cancer cases in the United States in 2023. Thus, the increasing prevalence of cancer is likely to create a great demand for diagnosis and treatment. Additionally, according to a January 2023 update by the Australian Government, an estimated 20,640 new cases of breast cancer were diagnosed in 2022. Thus, the huge burden of cancers among the population is expected to increase the demand for absorbable tissue spacers to provide adequate protection and to produce a strong protective barrier during radiotherapy, thereby boosting the market growth.

Various initiatives taken by the key market players, such as product launches, expansion, and partnerships, are expected to boost the market's growth during the forecast period. For instance, in February 2022, Palette Life Sciences, commercialized Palette’s portfolio of medical products. It expanded its Japanese offering, actively pursuing regulatory clearance for its Barrigel and Solesta brands. Such developments are expected to drive the growth of the market over the forecast period.

However, the high cost and lack of skilled professionals are some of the factors that are impeding the market growth over the forecast period.

The radiotherapy segment is expected to witness significant market growth over the forecast period owing to the factors such as the rising prevalence of cancer and the rising adoption of spacers during radiotherapy in treating various cancer types. For instance, according to an article published by BioMed Central Ltd in April 2022, the number of new cancer cases is estimated to increase by 20% by 2030 in Germany. Additionally, according to the American Association for Cancer Research (AACR) Cancer Progress Report 2022, in the past three years, there has been an increase in the number of cancer survivors living in the United States, reaching greater than 18 million as of January 1, 2022.

Additionally, the rising adoption of spacers during radiotherapy in treating various cancer types contributes to the segment's growth. For instance, according to an article published by the Journal of Radiation Research in July 2022, spacers had a favorable efficacy in the management of prostate radiotherapy in both external beam radiation therapy (EBRT) and brachytherapy. Also, according to an article published by Urology in October 2021, rectal spacers are being increasingly adopted into clinical practice to address radiation toxicity. The spacer material remains intact during the patient's radiation therapy (approximately 3 months), after which it is absorbed into the body and cleared in the urine.

North America is expected to show significant growth in the absorbable tissue spacer market owing to factors such as the increasing incidence and prevalence of cancers and progressing technological advancements in cancer treatment. For instance, according to the American Cancer Society update, in January 2023, an estimated 288,300 new prostate cancer cases and 52,550 new colon and rectum cases were reported in the United States.

In addition, the use of injectable rectal spacers to distance the anterior rectum from the prostate is a potential strategy to reduce the dose of unintended radiation to the rectum. For instance, according to an article published by MDPI, in October 2022, hydrogel spacers are gaining increasing popularity in the treatment regimen for prostate cancer in the United States. After the FDA approval of SpaceOAR, specialists received more referrals for hydrogel placements. Such advancement in cancer treatment is expected to drive the growth of the market over the forecast period.

The absorbable tissue spacer market is consolidated in nature due to the presence of a few companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well-known, including Biocomposites, Boston Scientific (Augmenix, Inc), Bioprotect Ltd., Palette Life Sciences, Inc., and Becton, Dickinson, and Company (CR Bard), among others.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support